[A19-88] Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.01.2020
Commission awarded on 15.10.2019 by the Federal Joint Committee (G-BA).
Maintenance treatment of platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum-based chemotherapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-16||Niraparib (ovarian cancer) - Addendum to Commission A19-88||Commission completed|
|G17-15||Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V||Commission completed|
|A20-98||Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A21-17||Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|